Agilisium, a leading life sciences domain-native AI services company, has announced a Rs 50 crore investment — close to $5.5 million — to fundamentally transform how pharmaceutical, biotech, and medtech enterprises operationalise AI.
At the heart of this initiative is the development and deployment of FDX, Forward Deployment Experts, a new professional standard defined by Agilisium built across four dimensions: Domain, AI & Technology, Consultative Solutioning, and Systems & Process Thinking.
Unlike traditional AI services, FDX professionals are embedded directly inside Life Sciences organizations working alongside scientific, regulatory, and commercial teams not advising from the outside but driving transformation from within.
The investment will reskill and deploy Agilisium's global workforce of more than 1,000 professionals as embedded AI transformation partners, making this the world's first forward deployment experts built exclusively for life sciences.
Life sciences organisations worldwide are accelerating adoption of context-aware agentic AI across drug discovery, clinical trials, pharmacovigilance, regulatory operations, and commercial operations yet most enterprise AI initiatives stall not because the technology fails, but because the talent required to operationalise it does not exist at scale.
Unlike traditional consulting model, Agilisium’s forward-deployment model combines deep life sciences domain expertise with AI engineering and data science capability and then keeps both inside the client’s organisation for the duration of the transformation.
Agilisium professionals sit beside scientists, clinical teams, regulatory leaders, and commercial stakeholders, designing, deploying, and continuously operating AI-driven capabilities rather than handing them over.
